Background {#sec0005}
==========

Brewer\'s yeast and baker\'s yeast were both *Saccharomyces cerevisiae* but different strains [@bib0075]. Invasive infection caused by *S. cerevisiae* is rare and usually occurs in patients in an immunocompromised situation, such as patients with solid cancers or hematological malignancies [@bib0080], [@bib0085], or patients who have undergone organ transplantation [@bib0080], [@bib0090], [@bib0095]. In immunocompetent patients, ingestion of the yeast has been associated with fever [@bib0100]. In this paper, we report a case of osteomyelitis caused by *S. cerevisiae* in a young female baker with no apparent immunodeficiency following trauma.

Case presentation {#sec0010}
=================

A previously healthy, 39-year-old female baker presented to the emergency department with a distal humerus fracture which was classified as a Cauchoix-Duparc type 3 fracture ([Fig. 1](#fig0005){ref-type="fig"}, [Fig. 2](#fig0010){ref-type="fig"}). She had been working at a bakery and her right upper extremity had been caught in an electrical bakery dough mixer. Surgical debridement, copious lavage and removal of all necrotic tissues were performed. The fracture was temporized and stabilized using an external fixation. Following surgery, she was treated with oral amoxicillin-clavulanic acid 3 g/day. On the fifth day after surgery, she underwent a second surgical debridement and reconstruction of the lost complex humeral tissue using the latissimus dorsi flap. External fixation was maintained to prevent sepsis, but realignment was performed. Bacterial cultures of deep surgical samples were positive for *Pseudomonas aeruginosa* and *Enterobacter cloacae*. She was treated with intravenous imipenem-cilastatin 1000 mg every 12 h and oral ciprofloxacin 500 mg every 8 h.

On the fifteenth day of her hospitalization, and despite antibiotherapy, she developed a purulent discharge from the posterolateral surface of the right arm. Bone samples obtained from surgical biopsies tested negative for bacterial pathogens, but fungal cultures grew for *S. cerevisiae*. Antifungal susceptibility testing, using the E-test assay, of this *S. cerevisiae* isolate showed low MICs for itraconazole (0.12 mg/L), fluconazole (4 mg/L), voriconazole (0.06 mg/L) and, amphotericin B (0.25 mg/L) and relatively higher MIC for posaconazole (0.25 mg/L). She was treated with hyperbaric oxygen therapy, voriconazole 250 mg twice daily orally and antibacterial therapy. Imipenem-cilastatin and oral ciprofloxacin were continued. The clinical outcome was favorable with the disappearance of purulent wound drainage ([Fig. 3](#fig0015){ref-type="fig"}) and she was discharged 25 days after her admission. Overall, she was treated with three months of antibacterials and nine months of voriconazole. An adjunctive treatment with hyperbaric oxygen therapy was performed. The skin had healed after six weeks. External fixation was removed after six weeks with a humeral nonunion repair by double external fixation ([Fig. 4](#fig0020){ref-type="fig"}).

Discussion {#sec0015}
==========

Saccharomyces bone and joint infections are extremely rare and have only previously reported in immunocompromised hosts [@bib0105], [@bib0110]. We report the first case of *S. cerevisiae* osteomyelitis in an immunocompetent patient who acquired the infection following traumatic humeral fracture using a bread dough mixer in a bakery.

To the best of our knowledge, only two cases of bone and joint infection caused *S. cerevisiae* have been reported including one case of arthritis in a 73-year-old woman with rheumatoid arthritis and Sjögren\'s syndrome [@bib0105] and one case of mandibular osteomyelitis in a 4-year-old boy who had undergone chemotherapy for an acute lymphoid leukemia [@bib0110].

Osteoarticular infection caused by *S. cerevisiae* may be a monomicrobial infection such as in the case of mandibular osteomyelitis [@bib0110]. However, this infection may also be polymicrobial, such as in the arthritis case reported [@bib0105] or misidentified such as in our case at the beginning of management that was initially diagnosed as osteomyelitis caused by *P. aeruginosa* and *E. cloacae*. *S. cerevisiae* was identified only at the second surgical deep samples culture. Physicians should consider *S. cerevisiae* as potential pathogen of osteomyelitis when infection has occurred in patients who have had wound contact with baker\'s or brewer\'s yeast.

Identification of *S. cerevisiae* was first performed by MALDI-TOF MS from the cultivation of a biopsy on Sabouraud medium and was then confirmed by sequencing of the ITS2 region of the rRNA gene as described by Cassagne et al. [@bib0115]. The antifungal agent of choice for the treatment of invasive infection by *S. cerevisiae* is unknown. *S. cerevisiae* is consistently susceptible to amphotericin B, to fluconazole and itraconazole. However, in vitro azole resistance have been reported [@bib0120]. After surgical debridement, oral antifungal agent with voriconazole was chosen in combination hyperbaric oxygen therapy and antibacterial therapy to treat this patient for early returning to rehabilitation center.

There is no data reported on hyperbaric oxygen for fungi osteomyelitis. Therefore, hyperbaric oxygen therapy was used as an adjunctive treatment of diabetic foot infections and refractory osteomyelitis for over sixty years [@bib0125], [@bib0130], [@bib0135], [@bib0140]. In our case, hyperbaric oxygen therapy has improved the postoperative care for this complex case of osteomyelitis caused by mixed bacterial and fungi infection.

Conclusion {#sec0020}
==========

Osteomyelitis due to *S. cerevisiae* is rare, but may occur in immunocompetent hosts, as our patient demonstrates. The organism should be considered as a potential cause of infection in patients who may have been at risk for inoculation with brewer\'s or baker\'s yeast, particularly when they fail to respond to antibacterial therapy and surgical debridement and lavage.
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